» Articles » PMID: 33479514

Diminished Reward Responsiveness is Associated with Lower Reward Network GluCEST: an Ultra-high Field Glutamate Imaging Study

Abstract

Low reward responsiveness (RR) is associated with poor psychological well-being, psychiatric disorder risk, and psychotropic treatment resistance. Functional MRI studies have reported decreased activity within the brain's reward network in individuals with RR deficits, however the neurochemistry underlying network hypofunction in those with low RR remains unclear. This study employed ultra-high field glutamate chemical exchange saturation transfer (GluCEST) imaging to investigate the hypothesis that glutamatergic deficits within the reward network contribute to low RR. GluCEST images were acquired at 7.0 T from 45 participants (ages 15-29, 30 females) including 15 healthy individuals, 11 with depression, and 19 with psychosis spectrum symptoms. The GluCEST contrast, a measure sensitive to local glutamate concentration, was quantified in a meta-analytically defined reward network comprised of cortical, subcortical, and brainstem regions. Associations between brain GluCEST contrast and Behavioral Activation System Scale RR scores were assessed using multiple linear regressions. Analyses revealed that reward network GluCEST contrast was positively and selectively associated with RR, but not other clinical features. Follow-up investigations identified that this association was driven by the subcortical reward network and network areas that encode the salience of valenced stimuli. We observed no association between RR and the GluCEST contrast within non-reward cortex. This study thus provides new evidence that reward network glutamate levels contribute to individual differences in RR. Decreased reward network excitatory neurotransmission or metabolism may be mechanisms driving reward network hypofunction and RR deficits. These findings provide a framework for understanding the efficacy of glutamate-modulating psychotropics such as ketamine for treating anhedonia.

Citing Articles

Mapping hippocampal glutamate in healthy aging with glutamate-weighted CEST (GluCEST) imaging.

Pecsok M, Robinson H, Atkins A, Calkins M, Elliott M, Mordy A Front Aging Neurosci. 2025; 16:1535158.

PMID: 39926356 PMC: 11802501. DOI: 10.3389/fnagi.2024.1535158.


Toward quantitative CEST imaging of glutamate in the mouse brain using a multi-pool exchange model calibrated by H-MRS.

Maguin C, Mougel E, Valette J, Flament J Magn Reson Med. 2024; 93(3):1394-1410.

PMID: 39449296 PMC: 11680732. DOI: 10.1002/mrm.30353.


The Glutamatergic Effects of Clinical Repetitive Transcranial Magnetic Stimulation in Depressed Populations: A Preliminary Meta-Analysis of Proton Magnetic Resonance Spectroscopy Studies.

Pecsok M, Mordy A, Cristancho M, Oathes D, Roalf D Psychopathology. 2024; :1-16.

PMID: 39004073 PMC: 11724939. DOI: 10.1159/000538690.


Elevating the field for applying neuroimaging to individual patients in psychiatry.

Roalf D, Figee M, Oathes D Transl Psychiatry. 2024; 14(1):87.

PMID: 38341414 PMC: 10858949. DOI: 10.1038/s41398-024-02781-7.


3.0 T multi-parametric MRI reveals metabolic and microstructural abnormalities in the posterior visual pathways in patients with thyroid eye disease.

Luo L, Zhang L, Huang H, Guan J, Zhang X, Lin Y Front Neurosci. 2024; 17:1306364.

PMID: 38274503 PMC: 10809795. DOI: 10.3389/fnins.2023.1306364.


References
1.
McMakin D, Olino T, Porta G, Dietz L, Emslie G, Clarke G . Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry. 2012; 51(4):404-11. PMC: 3536476. DOI: 10.1016/j.jaac.2012.01.011. View

2.
Uher R, Perlis R, Henigsberg N, Zobel A, Rietschel M, Mors O . Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med. 2011; 42(5):967-80. PMC: 3787526. DOI: 10.1017/S0033291711001905. View

3.
Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico P . The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2006; 21(5):461-71. DOI: 10.1177/0269881106069938. View

4.
Wolf D . Anhedonia in schizophrenia. Curr Psychiatry Rep. 2006; 8(4):322-8. DOI: 10.1007/s11920-006-0069-0. View

5.
Vrieze E, Demyttenaere K, Bruffaerts R, Hermans D, Pizzagalli D, Sienaert P . Dimensions in major depressive disorder and their relevance for treatment outcome. J Affect Disord. 2013; 155:35-41. PMC: 3932031. DOI: 10.1016/j.jad.2013.10.020. View